Research

FDA Gives Green Light for Multiple Sclerosis Stem Cell Trial

Tuesday, July 27, 2021 - 12:00pm

Non-profit research organization Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received FDA authorization for a randomized, double-blind, single center, Phase II clinical trial to assess the efficacy of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells in improving symptoms and quality of life in patients with mild-to-moderate multiple sclerosis (MS).

Key Points: 
  • Non-profit research organization Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received FDA authorization for a randomized, double-blind, single center, Phase II clinical trial to assess the efficacy of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells in improving symptoms and quality of life in patients with mild-to-moderate multiple sclerosis (MS).
  • A single infusion in the treatment group consists of 200 million stem cells, or approximately 1.2 billion stem cells per patient over the course of study.
  • HBSCRF remains the only organization globally to administer pure, fresh mesenchymal stem cells, an adult stem cell harvested from fat, in such high quantities over repeat treatments.
  • Clinical trial authorizations encompass COVID-19 prevention and treatment , traumatic brain injury , Parkinsons disease , and multiple sclerosis.

Arqit Announces Product to Protect Digital Assets From Quantum Attack

Tuesday, July 27, 2021 - 11:09am

Arqit Limited (Arqit), a global leader in quantum encryption technology, has today published a paper titled Digital Assets in a Post-Quantum World .

Key Points: 
  • Arqit Limited (Arqit), a global leader in quantum encryption technology, has today published a paper titled Digital Assets in a Post-Quantum World .
  • The Arqit digital assets paper explains how to secure digital assets and supporting infrastructure like wallets and exchanges from quantum attacks.
  • The Arqit digital assets research paper describes a new layer of technology to deliver security against quantum attacks.
  • Arqit supplies a unique quantum encryption Platform-as-a-Service which secures the communications links of any networked device against current and future forms of attack even from a quantum computer.

FlexCat™ by Unifrax Produces Increased Yield with Less Coking in Model PDH Study

Tuesday, July 27, 2021 - 12:00pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210727005241/en/
    FlexCat by Unifrax PDH testing results in partnership with hte GmbH.
  • Tested by hte GmbH, Unifrax targeted a model reaction of propane dehydrogenation (PDH) as a common industrial process and compared FlexCat to a literature derived and pellet-supported catalyst.
  • Unifraxs first step into industrial catalysis is a catalyst support material that has been proven to:
    Provide enhanced yield and selectivity.
  • FlexCat increased output by 20 percent in the initial cycle and retained at least 90 percent conversion activity during the subsequent cycle tested.

Global Ticket Market Is Poised to Grow by $10.77 Billion During 2021-2025 - ResearchAndMarkets.com

Tuesday, July 27, 2021 - 10:01am

This study identifies the increasing use of mobile apps for booking tickets as one of the prime reasons driving the ticket market growth during the next few years.

Key Points: 
  • This study identifies the increasing use of mobile apps for booking tickets as one of the prime reasons driving the ticket market growth during the next few years.
  • The report on the ticket market covers the following areas:
    The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.
  • The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary.
  • The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Curaleaf International Launches Second Medical Cannabis Flower Product for UK Market

Tuesday, July 27, 2021 - 7:00am

Curaleaf International (formerly EMMAC Life Sciences Group), (Curaleaf International), Europes largest vertically integrated cannabis company, is pleased to announce the launch of its second range of medical cannabis flower products for the UK market.

Key Points: 
  • Curaleaf International (formerly EMMAC Life Sciences Group), (Curaleaf International), Europes largest vertically integrated cannabis company, is pleased to announce the launch of its second range of medical cannabis flower products for the UK market.
  • The new products are being manufactured in the UK and will be an extension to Curaleaf Internationals existing range of medical cannabis flower and oil products.
  • Antonio Costanzo, CEO of Curaleaf International, commented: We are very pleased to extend our range of medical cannabis products for the UK market.
  • As a market leader, Curaleaf International is focused on solving the key patient and physician challenges relating to the price, accessibility, and sustainability of medical cannabis products.

Kiromic Announces the Acquisition of InSilico Solutions Leveraging on Bioinformatics and Artificial Intelligence to Advance Clinical Development on Its Outpatient Allogeneic CAR-T for Solid Tumors

Monday, July 26, 2021 - 11:55pm

Similar data from clinical trials will be used refine our understanding of efficacy and toxicity to improve treatment protocol and patient selection.

Key Points: 
  • Similar data from clinical trials will be used refine our understanding of efficacy and toxicity to improve treatment protocol and patient selection.
  • We will continually evaluate, implement, and improve our industry leading systems that will accelerate therapeutic development, manufacturing, and clinical testing of Kiromics off-the-shelf allogeneic CAR-T for solid tumors.
  • Under the agreement terms, Kiromic acquires InSIlico through a stock-swap operation, hiring the entire staff of InSIlico and their material and immaterial assets.
  • InSilico Solutions is a bioinformatics company with a stellar 10-year track record of developing innovative software for cancer researchers.

Dr. Revati Shreeniwas Joins ImmunoMet Therapeutics as Chief Medical Officer

Monday, July 26, 2021 - 10:38pm

ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-fibrotic and anti-cancer therapies, today announced that Dr. Revati Shreeniwas has joined the company as Chief Medical Officer.

Key Points: 
  • ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-fibrotic and anti-cancer therapies, today announced that Dr. Revati Shreeniwas has joined the company as Chief Medical Officer.
  • ImmunoMet is now positioned to advance the clinical development of IM156 in IPF patients.
  • Dr. Shreeniwas brings a wealth of clinical experience to ImmunoMet including extensive IPF clinical experience, said Dr. Benjamin Cowen, President and CEO of ImmunoMet Therapeutics.
  • Dr. Shreeniwas is a physician certified in internal medicine and pulmonary disease with 17 years of experience in pharmaceutical development.

AHF Commends the Resumption of HIV Treatment in Kenya – But More Is Needed

Monday, July 26, 2021 - 8:42pm

As a result, distribution of lifesaving HIV/AIDS prevention and treatment medications has resumed as of July 14, according to the US Embassy.

Key Points: 
  • As a result, distribution of lifesaving HIV/AIDS prevention and treatment medications has resumed as of July 14, according to the US Embassy.
  • The damage done to peoples lives and wellbeingparticularly childrens livesis irreversible and must never be repeated.
  • Ensure that HIV management is implemented holistically by taking into consideration prevention and diagnosis, care and treatment, and related essential commodities, including medications.
  • This is urgently needed to address current shortages of paediatric HIV treatment, viral load testing reagents, and HIV test kits.

Arcturus Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021

Monday, July 26, 2021 - 9:01pm

Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.

Key Points: 
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (222 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries).
  • In addition, please connect with us on Twitter and LinkedIn .
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005727/en/